LEADER 01771nam  2200433Ia 450 
001 9910693342003321
005 20050808090348.0
035   $a(CKB)5470000002362116
035   $a(OCoLC)61224223
035   $a(EXLCZ)995470000002362116
100   $a20050808d2005      ua             0
101 0 $aeng
135   $aurmn|---|||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aMedicaid drug rebate program$b[electronic resource] $einadequate oversight raises concerns about rebates paid to states : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives /$fstatement of Kathleen King
210  1$a[Washington, D.C.] :$cU.S. Government Accountability Office,$d[2005]
225 1 $aTestimony ;$vGAO-05-850 T
300   $aTitle from title screen (viewed on July 27, 2005).
300   $a"For release ... June 22, 2005."
300   $aPaper version available from: U.S. Government Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548.
320   $aIncludes bibliographical references.
517   $aMedicaid drug rebate program 
606   $aMedicaid
606   $aDrugs$xPrices$zUnited States$xStates
606   $aPrescription pricing$zUnited States$xStates
615  0$aMedicaid.
615  0$aDrugs$xPrices$xStates.
615  0$aPrescription pricing$xStates.
700   $aKing$b Kathleen$01382817
712 02$aUnited States.$bCongress.$bHouse.$bCommittee on Energy and Commerce.$bSubcommittee on Health.
712 02$aUnited States.$bGovernment Accountability Office.
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910693342003321
996   $aMedicaid drug rebate program$93426833
997   $aUNINA